文献速递神经免疫

多发性硬化临床试验人群中合并症患病率的研究

Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
PubMed 文献 · Neurology · 2024-02-13

该研究基于17项III期多发性硬化疾病修正治疗试验的个体数据,采用两阶段Meta分析估计合并症患病率。结果显示46.5%的试验参与者至少有1种合并症,抑郁(16.45%)和高血压(10.16%)最常见。尽管有合并症者被纳入试验,但与一般多发性硬化人群相比可能仍被低估。

要点

  • III期多发性硬化试验中46.5%的参与者至少有1种合并症。
  • 抑郁(16.45%)和高血压(10.16%)是最常见的合并症。
  • 有合并症者被纳入试验,但相较一般多发性硬化人群可能仍被低估。

核心结论

  • 有合并症者被纳入多发性硬化临床试验,但与一般多发性硬化人群相比可能仍被低估。
  • 鉴于试验人群中的合并症患病率及合并症与疾病活动相关的研究,合并症可能影响临床试验结局。

研究设计与样本

  • 研究为两阶段Meta分析,纳入17项III期多发性硬化疾病修正治疗试验的个体水平数据,共17926名参与者。
  • 其中14项试验纳入复发型多发性硬化参与者,3项纳入进展型多发性硬化参与者。
  • 研究遵循Maelstrom回顾性协调指南,基于病史数据对合并症进行分类。

主要发现

  • 合并症汇总患病率:1种合并症为25.0%(95%CI 23.0-27.0,I²=89.9),2种为11.4%(95%CI 9.3-14.0,I²=96.3),≥3种为6.0%(95%CI 4.2-8.4,I²=97.7)。
  • 抑郁是最常见的合并症,患病率为16.45%(95%CI 12.96-20.88,I²=98.3),其次为高血压10.16%(95%CI 8.61-11.98,I²=93.2)。
  • 年龄较大和女性参与者与合并症数量增加相关。
  • 年龄较大和男性参与者高脂血症患病率更高,年龄较大和女性参与者抑郁和焦虑患病率更高。
  • 各试验间异质性高。

关键数值与推荐

  • 考虑的慢性合并症包括抑郁、焦虑、高血压、高脂血症、偏头痛、糖尿病和慢性肺病,由国际多发性硬化临床试验咨询委员会推荐。
  • 合并症数量分类为0、1、2或≥3种。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 各试验间异质性高,抑郁I²=98.3,高血压I²=93.2,1种合并症I²=89.9,2种I²=96.3,≥3种I²=97.7。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Comorbidity is common in multiple sclerosis (MS) with the most prevalent conditions being depression, anxiety, hypertension, and hyperlipidemia. Limited information regarding the representation of comorbidity status is available from phase III clinical trials in MS leading to concern about the potential underrepresentation of individuals with comorbidity in clinical trials. The objective was to estimate the prevalence of comorbidities in MS clinical trial populations. METHODS: Individual-level data from multiple sponsors were requested for a 2-stage meta-analysis of phase III clinical trials of MS disease-modifying therapies. To ensure consistency of our approach across trials, we followed the Maelstrom retrospective harmonization guidelines. Chronic comorbidities at clinical trial enrollment recommended by the International Advisory Committee on Clinical Trials in MS were considered (depression, anxiety, hypertension, hyperlipidemia, migraine, diabetes, chronic lung disease). Additional comorbidities were also classified. Classification was based on medical history data. Individual comorbidities were summed and categorized as 0, 1, 2, or ≥3. We report the pooled prevalence (95% confidence interval [95% CI]) of comorbidity. The pooled prevalence and prevalence ratios across age, sex, race, disability level, and treatment were also reported. Heterogeneity was assessed using the I2 statistic. RESULTS: Seventeen trials involving 17,926 participants were included. Fourteen trials enrolled participants with relapsing MS (RMS) while 3 enrolled participants with progressive MS (PMS). The distributions of sex, age, and disability level were generally consistent within RMS and PMS trials. When pooled, almost half of trial participants (46.5%) had ≥1 comorbidity (1: 25.0%, 95% CI 23.0-27.0, I2 = 89.9; 2: 11.4% [9.3-14.0], I2 = 96.3; ≥3: 6.0% [4.2-8.4], I2 = 97.7). Depression (16.45% [12.96-20.88], I2 = 98.3) was the most prevalent comorbidity reported, followed by hypertension (10.16% [8.61-11.98], I2 = 93.2). Heterogeneity was high across trials. Older age and female participants were associated with increased number of comorbidities. Older individuals and male participants had a higher prevalence of hyperlipidemia, while older individuals and female participants had a higher prevalence of depression and anxiety. DISCUSSION: Individuals with comorbidities are included in clinical trials, although they may still be underrepresented compared with the general MS population. Given the comorbidity prevalence in the trial populations and studies suggesting an association of comorbidities with disease activity, comorbidity may influence outcomes in clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Salter A, Lancia S, Kowalec K, et al. Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations. Neurology. 2024. PMID: 38350062. doi:10.1212/WNL.0000000000209135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。